Skip to main content

Table 1 Neoplastic and non-neoplastic lesions observed in hepatic tissue of female Sprague-Dawley rats following 104 weeks of chronic p.o. exposure

From: Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands

 

100 ng/kg/day TCDD

30 ng/kg/day PCB126

300 ng/kg/day PCB126

1000 ng/kg/day PCB126

1000 μg/kg/day PCB153

Number of Rats Examined

53

55

53

53

53

Hepatocyte Hypertrophy

52**a

23**

42**a

49**a

39**a

Multinucleated Hepatocytes

51**b

2

19**

49**b

NA

Fatty Change, Diffuse

48**b

7

30**

47**b

21**

Bile Duct Hyperplasia

53**b

7

14**

45**b

10

Bile Duct Cyst

21**

6

3

12*

NA

Oval Cell, Hyperplasia

53**

1

10**

40**

NA

Necrosis

17**

2

11

17**

NA

Pigmentation

53**b

11**

48**b

48**b

5

Eosiniphilic Focus

44**

10

17

17

NA

Inflammation

49**

40

51**

51**

NA

Nodular Hyperplasia

36**

NA

3

39**

1

Portal Fibrosis

27**

NA

2

10**

NA

Cholangiofibrosis

31**

1

3

22**

1

Toxic Hepatopathy

53**b

6*

39**

49**b

NA

Hepatocholangioma

17**

NA

NA

3

2

Hepatocellular Adenoma

13**

2

2

7*

NA

Cholangiocarcinoma

25**

NA

5*

22**

NA

  1. Shown are the number of animals in each treatment group which exhibit the indicated liver pathology following exposure to TCDD (100 ng/kg/day), PCB126 (30, 300 or 1000 ng/kg/day) or PCB153 (1000 μg/kg/day). Data acquired from the National Toxicology Program [4, 5, 8]. a Response also significantly increased (p ≤ 0.01) following 13 and 52 weeks of exposure; b Response also significantly increased (p ≤ 0.01) following 52 weeks of exposure; * Statistically significant when compared to control with p-value ≤ 0.05; ** Statistically significant when compared to control with p-value ≤ 0.01; NA - not available.